Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Neuraxpharm Aims For Sales Of €400m By Year End

After recently rebranding the company, Neuraxpharm has put expansion plans in place that have allowed it to reach over 70% of the European central nervous system market, resulting in projections of organic sales growth of 10% and gross sales of €400m for this year.

Sales & Earnings Strategy

Glenmark Says Makeover To Be Finished By End 2019-20 As It Seeks To Spur Growth

Glenmark says its reorganization into three entities – one focused on generics and specialty drugs, the second on APIs and the third on new drug innovation – will be wrapped up by year-end as it seeks to accelerate sluggish earnings and reduce heavy debt.

Strategy Sales & Earnings

ANI Pharma Looks to Buy A Platform For Its Push Into Injectables

Having swelled its pipeline of US injectable drugs through an acquisition, ANI Pharmaceuticals is on the lookout for attractive manufacturing assets.

Business Strategies M & A

China’s Luye Pursues Global Differentiation Strategy

Luye Pharma says it is making sound progress in developing a pipeline of added-value injectables and transdermal patches, while clinical trials for two biosimilars are also moving forward.

Value-Added Medicines Neurology

Auditor Casts Doubt On Julphar’s Future Amid Saudi Ban

As it struggles to restore exports to one of its key markets, Saudi Arabia, following a facility inspection, UAE-based Julphar is continuing to post large losses on tumbling turnover.

Saudi Arabia Compliance

Glenmark On Course For Xolair Biosimilar Deal, US Capital Raise For Innovation

Glenmark appears close to sewing up a deal for its biosimilar version of Novartis/Genentech's Xolair amid the firm's ongoing focus on partnering out some key assets. It also expects to kick off plans to raise capital in the US for its innovation business in Q4 of fiscal 2019-20.

Commercial Strategy
See All
UsernamePublicRestriction

Register

Advertisement